Recent 8-K filings for GLSI

• June 17, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Greenwich LifeSciences raises ~$2.5M in private placement with CEO at $14.30/share

  CEO Snehal Patel purchased 174,825 shares at $14.30 (June 12 closing price) for ~$2.5M gross proceeds.

• February 14, 2024, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Greenwich LifeSciences expands Phase III Flamingo-01 arm to 250 patients; European sites pending

  DSMB recommended continue as is; no serious adverse events related to GLSI-100 reported to date.

• July 12, 2022, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA removes clinical hold on Greenwich LifeSciences' Flamingo-01 Phase III trial

  FDA formally removed the clinical hold on July 11, 2022, allowing the Flamingo-01 Phase III trial to proceed.

• July 12, 2022, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Greenwich LifeSciences enters $100M ATM equity offering agreement with Jefferies

  Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock up to $100M.

• July 11, 2022, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

  FDA clinical hold on GLSI-100 Phase III Flamingo-01 remains; manufacturing data submitted, review ongoing

  FDA placed clinical hold on Flamingo-01 trial for GLSI-100 (GP2) in HER2/neu positive patients, citing manufacturing issues.

• December 13, 2021, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence

  22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).

• November 10, 2021, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions

  Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).

Materiality & sentiment trend

Max materiality 0.80 · Median 0.47 · Most common event other_material

3 positive 1 negative 12 neutral

source · GLSI on sec.gov